Previous Close | 2.6200 |
Open | 2.6100 |
Bid | 2.6600 x 2900 |
Ask | 2.7600 x 3100 |
Day's Range | 2.5800 - 2.6700 |
52 Week Range | 1.4600 - 3.1600 |
Volume | |
Avg. Volume | 1,818,128 |
Market Cap | 751.406M |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9400 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for LAB
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin"). Thomas Carey, Chairman of the Standard BioTools Board of Directors, said, “W
Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript February 28, 2024 Standard BioTools Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.13. LAB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to […]
Standard BioTools ( NASDAQ:LAB ) Full Year 2023 Results Key Financial Results Revenue: US$106.3m (up 8.6% from FY...